Search

everythinglearnresearchcommunity

for

Search:↓

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Hair growth is influenced by interactions between skin layers, growth factors, and hormones, but the exact mechanisms are not fully understood.

Hormone imbalances can cause specific skin changes, which may help in early detection of endocrine disorders.

Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.

Male rats grow hair faster than females, and certain hormones can slow or slightly increase hair growth, but not significantly beyond natural rates.

Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.

Skin problems can be signs of hormone-related disorders and recognizing them early is important for treatment.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Finasteride can cause lasting sexual dysfunction, depression, and other side effects, needing more research for treatment.

Topical spironolactone cream doesn't cause hormone-related side effects in the body.

Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.

BeauTop improves hair growth in androgenetic alopecia patients.

Hormone imbalances from the pituitary, thyroid, and adrenal glands can cause infertility, but treating these disorders can improve fertility.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Gender-affirming hormone therapy affects metabolism differently based on treatment type.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

Marijuana use may be linked to lower TSH levels, but the exact cause is unclear.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Follistatin helps hair growth and cycling, while activin prevents it.

PRP treatment improves hair density and thickness for alopecia, but needs more research.

Diagnosing hyperandrogenism in women is complex and requires accurate testing methods and consideration of SHBG levels.

People with hidradenitis suppurativa often have lower vitamin D levels, weaker hip bones, and altered bone metabolism markers.

Hormone imbalances from endocrine diseases can cause various skin conditions that help diagnose and treat these diseases early.

Androgenetic alopecia is not linked to higher risks of hypertension or hyperaldosteronism.

Removing Sprouty genes in mice causes various hormone-related issues but does not increase cancer risk by one year of age.

17β-estradiol may help hair growth by increasing cannabinoid receptor type 1.

The nucleus is key in controlling skin growth and repair by coordinating signals, gene regulators, and epigenetic changes.

Follistatin is important for hair growth and could help treat hair loss.

Manipulating the catagen and telogen phases of hair growth could lead to treatments for hair disorders.